230 related articles for article (PubMed ID: 31182765)
1. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.
Plummer C; Michael A; Shaikh G; Stewart M; Buckley L; Miles T; Ograbek A; McCormack T
Br J Cancer; 2019 Jul; 121(2):109-116. PubMed ID: 31182765
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.
Minion LE; Tewari KS
Expert Rev Anticancer Ther; 2017 Mar; 17(3):191-198. PubMed ID: 27748633
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab toxicities and their management in ovarian cancer.
Randall LM; Monk BJ
Gynecol Oncol; 2010 Jun; 117(3):497-504. PubMed ID: 20363017
[TBL] [Abstract][Full Text] [Related]
4. Treatment of bevacizumab-induced hypertension by amlodipine.
Mir O; Coriat R; Ropert S; Cabanes L; Blanchet B; Camps S; Billemont B; Knebelmann B; Goldwasser F
Invest New Drugs; 2012 Apr; 30(2):702-7. PubMed ID: 20878444
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and ovarian cancer.
Sato S; Itamochi H
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab-induced hypertension: pathogenesis and management.
Syrigos KN; Karapanagiotou E; Boura P; Manegold C; Harrington K
BioDrugs; 2011 Jun; 25(3):159-69. PubMed ID: 21627340
[TBL] [Abstract][Full Text] [Related]
7. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
Raouf S; Bertelli G; Ograbek A; Field P; Tran I
Future Oncol; 2019 Feb; 15(5):543-561. PubMed ID: 30379088
[TBL] [Abstract][Full Text] [Related]
8. Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer.
Palavalli Parsons LH; Roane B; Manders DB; Richardson DL; Kehoe SM; Carlson M; Miller DS; Lea JS
Am J Clin Oncol; 2018 Oct; 41(10):933-937. PubMed ID: 28817390
[TBL] [Abstract][Full Text] [Related]
9. Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX;
N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.
Li M; Kroetz DL
Pharmacol Ther; 2018 Feb; 182():152-160. PubMed ID: 28882537
[TBL] [Abstract][Full Text] [Related]
11. [Bevacizumab and arterial hypertension or proteinuria: management].
Senellart H; Bennouna J
Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832
[TBL] [Abstract][Full Text] [Related]
12. Improved survival with bevacizumab in advanced cervical cancer.
Tewari KS; Sill MW; Long HJ; Penson RT; Huang H; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Michael HE; Monk BJ
N Engl J Med; 2014 Feb; 370(8):734-43. PubMed ID: 24552320
[TBL] [Abstract][Full Text] [Related]
13. Hypertension and Neuroimaging Changes After Bevacizumab for Retinopathy of Prematurity.
Twitty G; Weiss M; Albayram MS; O'Mara K; Mowitz ME
Pediatrics; 2020 Jan; 145(1):. PubMed ID: 31806670
[TBL] [Abstract][Full Text] [Related]
14. A case report of endorectal displacement of a right ureteral stent following radiochemotherapy and Bevacizumab.
Tognarelli A; Faggioni L; Manassero F; Gadducci A; Selli C
BMC Urol; 2019 Dec; 19(1):128. PubMed ID: 31818277
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis inhibitors for patients with ovarian cancer: a meta-analysis of 12 randomized controlled trials.
Li X; Zhu S; Hong C; Cai H
Curr Med Res Opin; 2016; 32(3):555-62. PubMed ID: 26652645
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
17. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer.
Wang TS; Lei W; Cui W; Wen P; Guo HF; Ding SG; Yang YP; Xu YQ; Lv SW; Zhu YL
Indian J Cancer; 2014 Mar; 51 Suppl 3():e95-8. PubMed ID: 25818743
[TBL] [Abstract][Full Text] [Related]
19. A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Stähle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MK; Oza AM;
N Engl J Med; 2011 Dec; 365(26):2484-96. PubMed ID: 22204725
[TBL] [Abstract][Full Text] [Related]
20. Managing patients with metastatic colorectal cancer on bevacizumab.
Lemmens L; Claes V; Uzzell M
Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
